Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout.

"Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the efficiency of our development organization, and the importance we place on our gout program -- a program we intend to expand with second-generation compounds from our exciting ongoing research in this area," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Earlier this quarter, we initiated a Phase 2a proof-of-concept study of RDEA806, a prodrug of RDEA594, which should allow us to provide an early confirmation of RDEA594's activity in the target population of patients with gout."

This Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult male volunteers.

About Gout

An estimated 3-5 million people in the United States, and approximately 5 million people in the European Union, suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments: ... Capsule Endoscopes , Capsule Endoscopy Data Recorders ... also provides company shares and distribution shares data for ...
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5
... 07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corporation announced today ... vaccine elicited neutralizing,IgA mucosal antibodies in a ... as a possible first line of defense,against ... by Sylvain,Fleury, Ph.D., Mymetics' Chief Scientific Officer, ...
... 7, 2007 - Dynogen,Pharmaceuticals, Inc. reported positive ... trial of DDP733 for,gastroesophageal reflux disease (GERD). ... DDP733 as a treatment for,nocturnal GERD (NGERD). ... significance over placebo on the primary endpoint ...
Cached Medicine Technology:Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4
(Date:7/28/2014)... July 28, 2014 A St. Jude ... adult survivors of childhood cancer more than doubled their ... by failing to follow a heart-healthy lifestyle. The results ... , Almost 32 percent of the 1,598 adult survivors ... an umbrella term for health risk factors like high ...
(Date:7/28/2014)... July 2014: ESC Congress 2014 promises to be bigger, ... Keith Fox, Chair of the Congress Programme Committee. The ... most influential cardiovascular event every year in August. Record ... this year and the congress is on track to ... , Asked why an extra hot line session ...
(Date:7/28/2014)... group of researchers in Taiwan has developed a new ... early complication of diabetes sooner, when it is more ... in clinical trials, it may pave the way for ... complication, called diabetic autonomic neuropathy, which is common among ... The condition progressively affects the autonomic nerves controlling vital ...
(Date:7/28/2014)... Brea, CA (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Brea campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Brisbane, Australia (PRWEB) July 28, 2014 ... achieve a happier lifestyle can often be a struggle ... international channel, psychic and medium, Lynette Leckie-Clark provides simple ... new book “The Magic of You.” With inspiring spiritual ... thinking, you can find empowerment, confidence and motivation for ...
Breaking Medicine News(10 mins):Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... being fed contaminated feed is causing concern among the people. The ... years . The FDA is quick to play down the fear ... ,This concern came to light after some 38 chicken farms in ... farms fed the chicken for human consumption with the contaminated feed. ...
... C (HCV), survival has improved over time. However, for ... to a study in the issue of Liver Transplantation. ... reason for liver transplantation in the U.S., however, previous ... as well to liver transplantation. The difference has become ...
... governor, James E. McGreevy appears to be knocking on a ... the news for the right reasons. He has been ... ,Former Gov. James E. McGreevy, who was brought up as ... on Sunday at St. Bartholomew's Church in New York. He ...
... said the government is working to draft a law allowing ... of genetic disorders. ,"We are studying it from ... choice to have the abortion will be under the umbrella ... religious and social environment," Ali Shakar of the ministry of ...
... more than twice as likely to also have symptoms of ... not have migraines, according to research. ,The study involved ... screening questionnaire within 90 days after returning from one year ... the soldiers, or 60 percent, completed the questionnaire. Of those, ...
... warming, but only few act. ,The ... has two parts. One, human beings get stubbornly comfortable in ... programmed to act in its own best interests - and ... point. ,In addition, the overwhelming size and abstract ...
Cached Medicine News:Health News:Tainted Pet Food a Health Risk for Human? 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2Health News:Why Humans Fail to Act on Climate Change 2Health News:Why Humans Fail to Act on Climate Change 3
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: